Teko e Felletse ho Phekola Radiation Dermatitis ho Bakuli ba nang le Kankere ea Matsoele

Lutris Pharma kajeno e phatlalalitse hore e phethetse ho ngolisoa ha karolo ea bobeli ea teko ea kliniki ea 1/2 ea motsoako oa lead, LUT014, buka ea B-Raf inhibitor, e sebelisoang ka holimo, bakeng sa phekolo ea dermatitis e bakoang ke mahlaseli (RD) ho bakuli ba nang le lefu la tsoekere. kankere ea matsoele. Lintlha tsa maemo a holimo li lebelletsoe kotareng ea boraro ea 2022.

Karolo ea bobeli ea thuto ea karolo ea 1/2 e laoloang ka mokhoa o sa reroang, e sa boneng habeli, e sa boneng habeli, e ngolisitse bakuli ba 20 mme e etselitsoe ho lekola katleho ea LUT014 e tsamaisoang ka holimo ho bakuli ba mofetše oa matsoele ba nang le RD. Bakuli ba 'nile ba etsoa ka mokhoa o sa tloaelehang ka karolelano ea 1: 1 ho fumana LUT014 e tsamaisoang ka holimo kapa placebo ka matsatsi a 28, e lateloa ke nako ea likhoeli tse 2.

Qetello ea mantlha ea karolo ea bobeli ke phetoho ea ho teba ha dermatitis ea radiation e ipapisitseng le lethathamo la lipotso tsa Dermatology Life Quality Index (QoL) matsatsing a 14. Liphello tsa bobeli li kenyelletsa phetoho ho matla a mahlaseli a kotsi a mahlaseli a kotsi a thehiloeng lethathamong la lipotso tsa Dermatology QoL le liketsahalo tsa liketsahalo tse bohloko tse hlahang kalafo joalokaha li hlahlobiloe ke Common Terminology Criteria for Adverse Events (CTCAE) ho tloha qalong ho ea libeke tse 12.

"Liphetho tse matla tse hlokometsoeng ho tsoa ho bakuli ba robeli Karolong ea 1 ea teko ea LUT014 ho phekola RD, li re file kholiseho e eketsehileng mabapi le bokhoni ba phekolo ena 'me tsa re susumelletsa ho qala karolo ea 2, pele ho moo re neng re lebeletse," ho boletse Benjamin W. Corn, MD, Ofisiri e ka Sehloohong ea Bongaka ea Lutris Pharma. "Ho ntse ho e-na le tlhokahalo ea bohlokoa e sa finyelloang har'a bakuli ba nang le kankere ea matsoele ba tšoeroeng ke RD, bao hona joale ho seng mekhoa ea phekolo e amohelehang bakeng sa bona. LUT014 e na le mokhoa o ikhethileng oa liketso o ikemiselitseng ho leka-lekanya ho senyeha ha lisele tse karolong ea basal ea letlalo ka ho ntlafatsa ho ata ha lisele, kahoo ho ka khona ho fetola liphello tsa RD.

"Ho ngolisoa ha mokuli oa ho qetela karolong e 'meli e foufetseng ea karolo ea bobeli ea thuto ea rona ea 1 / 2 ho re tlisetsa mohato o le mong oa tsoelo-pele ea LUT014 e le phekolo ea RD," ho boletse Noa Shelach, Ph.D. Lutris Pharma. "Ho hakanngoa hore hoo e ka bang halofo ea bakuli ba mofetše ba phekoloa ka phekolo ea mahlaseli, selemo le selemo, 'me boholo ba bakuli ba kankere ea matsoele, haholo-holo, ba ba le mofuta o itseng oa RD. Ho latela mokhoa oa ts'ebetso oa LUT014, re lumela hore LUT104 e ka ba le phello e kholo ho palo ena ea bakuli. Re labalabela ho tlaleha lintlha tse matla tsa teko ena kotareng ea boraro ea selemo sena. ”